Tag: nivolumab
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD
Posted: April 16, 2020
After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life...
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in...
By Neal Ready, MD, PhD
Posted: February 12, 2020
Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of...
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With...
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on...
Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?
By Si-Yang Liu, MD, and Yi-Long Wu, MD
Posted: November 12, 2019
In the twentieth century, adjuvant chemotherapy became the standard of care for resected NSCLC...